Current Report Filing (8-k)
February 05 2014 - 4:17PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): February 5, 2014
Avanir Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-15803 |
|
33-0314804 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
|
|
|
20 Enterprise, Suite 200, Aliso Viejo, California |
|
92656 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrants telephone number, including area code:
(949) 389-6700
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02. |
Results of Operations and Financial Condition. |
On February 5, 2014, Avanir Pharmaceuticals, Inc.
(the Company) issued a press release announcing its financial results for the three months ended December 31, 2013 (the Earnings Press Release). A copy of the Earnings Press Release is furnished herewith as
Exhibit 99.1.
The information set forth under Item 2.02 and in Exhibit 99.1 shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits
|
|
|
Exhibit No. |
|
Description |
|
|
99.1 |
|
Earnings Press Release, dated February 5, 2014 |
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Date: February 5, 2014 |
|
|
|
Avanir Pharmaceuticals, Inc. |
|
|
|
|
|
|
|
|
By: |
|
/s/ Christine G. Ocampo |
|
|
|
|
|
|
Christine G. Ocampo |
|
|
|
|
|
|
Vice President, Finance |
-3-
Exhibit Index
|
|
|
Exhibit No. |
|
Description |
|
|
99.1 |
|
Earnings Press Release, dated February 5, 2014 |